Results 11 to 20 of about 15,812 (182)
The biology of thrombopoietin and thrombopoietin receptor agonists [PDF]
Thrombopoietin (TPO) is the major physiological regulator of platelet production. TPO binds the TPO receptor, activates JAK and STAT pathways, thus stimulating megakaryocyte growth and platelet production. There is no "sensor" of the platelet count; rather TPO is produced in the liver at a constant rate and cleared by TPO receptors on platelets.
openaire +2 more sources
Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case series
Thrombocytopenia is a relatively common complication following allogeneic hematopoietic stem cell transplantation and is associated with increased bleeding, transfusion requirements, chronic graft-versus-host disease, and all-cause mortality.
Guido Lancman +2 more
doaj +1 more source
Plasma thrombopoietin levels as additional tool in clinical management of thrombocytopenic neonates
Plasma thrombopoietin (Tpo) levels distinguish thrombocytopenia resulting from increased platelet destruction or decreased platelet production. We investigated whether measuring plasma Tpo levels in thrombocytopenic newborns is of diagnostic value to ...
Leendert Porcelijn +5 more
doaj +1 more source
Pathophysiology, classification, and complications of common asymptomatic thrombocytosis in newborn infants [PDF]
We frequently encounter newborn infants with thrombocytosis in the neonatal intensive care unit. However, neonatal thrombocytosis is not yet fully understood.
Ga Won Jeon
doaj +1 more source
C3G is a Rap1 guanine nucleotide exchange factor that controls platelet activation, aggregation, and the release of α-granule content. Transgenic expression of C3G in platelets produces a net proangiogenic secretome through the retention of ...
Luis Hernández-Cano +17 more
doaj +1 more source
Advances in management of pediatric chronic immune thrombocytopenia: a narrative review [PDF]
Immune thrombocytopenia (ITP) is a disease in which thrombocytopenia occurs because of immune-mediated platelet destruction and decreased platelet production.
Jae Min Lee
doaj +1 more source
INTRODUCTION: Thrombopoietin (TPO) being the major regulator of megakaryopoiesis is expected to show a compensatory increase in immune thrombocytopenia (ITP), however, it is not so observed.
Gurleen Oberoi +5 more
doaj +1 more source
Clinical Indications for Thrombopoietin and Thrombopoietin-Receptor Agonists [PDF]
Thrombocytopenia is a common hematologic disorder. Stimulation of thrombopoiesis may reduce the risk for thrombocytopenia-induced bleeding, prevent severe thrombocytopenia, and reduce the need for platelet transfusion. The key cytokine is thrombopoietin (TPO).
openaire +2 more sources
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis share driver mutations that either activate the thrombopoietin receptor, MPL, or indirectly activate it through mutations in the gene for JAK2, its ...
Jerry L. Spivak, Alison R. Moliterno
doaj +1 more source
Thrombopoietin and platelet aggregation in patients with stable coronary artery disease
Thrombopoietin (TPO) may facilitate platelet activation and aggregation. However, data on the impact of TPO on platelet aggregation in patients with stable coronary artery disease (CAD) are scarce.
Sanne Bøjet Larsen +5 more
doaj +1 more source

